VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a...
Clinical Trial
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide...
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0)...
H1 Partners with CTI to Streamline Clinical Trial PI and Site Selection for More Inclusive and Efficient Trials
Leading Contract Research Organization integrates H1’s Trial Landscape platform to optimize global site selection, enhance diversity efforts, and streamline operational...
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without...
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical...
New MammoCAT Advanced Mammography System Offers Substantial Improvements in Dense Breast Imaging
Fischer Imaging Delivers MammoCAT to Johns Hopkins University for Preclinical TestingATLANTA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Mammograms are one...
Ori Biotech and Fresenius Kabi Collaborate to Advance Modular, Scalable Manufacturing of Cell and Gene Therapies
New collaboration showcases successful integration of Ori's IRO Platform with Cue and Lovo processing systems to enhance efficiency in CGT...
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation...
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
- Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis – - REGAL Independent Data Monitoring Committee...
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of...
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal...
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY...
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist...
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of...
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem BiosciencesBELTSVILLE, Md., Dec. 10, 2024...
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT)...
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and...
Artificial Intelligence in Medical Diagnostics Market to Hit USD 4.72 Billion by 2029 with 22.5% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla. , Dec. 9, 2024 /PRNewswire/ -- The global AI in medical diagnostics market is likely to grow from...
Zero Candida Receives South African Patent for its ZC- 01 device
Announces IP plans to obtain a worldwide patent portfolio in 2025 VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ -- Zero Candida...